NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Exact Sciences Corp (EXAS) Stock Analysis

Exact Sciences Corp (EXAS) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

EXAS

$104.91

$0.00 (0.00%)

Last trade March 23, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EXAS with… →

EXAS Key Statistics

As of Mar 23, 2026
Trading
Open
$104.91
Previous Close
$104.91
52-Week Range
38.81–104.98
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.44
Valuation
Market Cap
$20.03B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
55.22
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.17
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.10
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.40%
1-Year Return
+129.96%
Dividend and dates
Avg Volume
2.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EXAS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.30%
2025+80.74%
2024 (partial year)+0.14%

As of March 23, 2026.

EXAS Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricEXASDiagnostics & Research medianvs median
P/S ratio6.174.9924% above
Profit margin−6.40%0.00%6.4 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Exact Sciences Corp (EXAS) is capitalised at $20.03B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 7,100.

The 52-week range on file runs from $38.81 to $104.98. EXAS last closed at $104.91 on March 23, 2026. The close was unchanged from the previous session. The latest close sits 170.32% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $3.25B. The reported profit margin is −6.4%. That is 6.4 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −1.1.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 55.22. The price-to-sales ratio is 6.17. On price-to-sales that is 23.59% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +129.96%. Beta against the wider market is reported at 1.44. Daily returns over the trailing 1 year annualize to a volatility of 44.3%.

Growth & Income

The record shows no dividend for EXAS.

2026 is still running; the price is +3.30% year to date. The record holds one complete calendar year, 2025, which returned +80.74%.

Peer Comparison

Exact Sciences Corp (EXAS) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Exact Sciences Corp EXAS $20.03B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Exact Sciences Corp has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of March 23, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Visit website →